Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New US, EU Climate-Related Disclosure Requirements Will Have Ripple Effects Through Value Chains

Reporting on GHG emissions and climate-related risks to kick off in 2026 in the EU and California

Executive Summary

Reporting requirements in the EU, California, and likely soon at the US Securities and Exchange Commission will have companies probing deeper in their value chains for sustainability information and attempting to calculate Scope 3 greenhouse gas emissions with limited resources, potentially with unfavorable implications for smaller businesses, industry advocates say.

You may also be interested in...



ESG In 2024: Stakeholder Views From ‘Strategic Imperative’ To ‘Largely A Nonsense’

Medtech Insight and HBW Insight reached out to industry stakeholders for feedback on new climate-related disclosure requirements and growing environmental, social and governance (ESG) pressures on businesses.

ESG In 2024: Stakeholder Views From ‘Strategic Imperative’ To ‘Largely A Nonsense’

HBW Insight and Medtech Insight reached out to industry stakeholders for feedback on new climate-related disclosure requirements and growing environmental, social and governance (ESG) pressures on businesses.

MTI 100: Macro Challenges Make Demands Of Newly Resilient Medtechs

Global medtechs had a big enough challenge with COVID-19 and its aftermath before the full-scale regional conflict in Ukraine added more uncertainty to the question of when market normality would return.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT148562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel